Clinical Trial Update: BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)

View source ↗

Summary

This clinical trial update reports on the BEAR study evaluating BEYFORTUS (nirsevimab) for preventing medically attended respiratory syncytial virus events in i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• BEYFORTUS (Nirsevimab)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Respiratory Syncytial Virus | Status: COMPLETED